InsidersTradesSigma
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
Browse the detailed record of transactions filed by Kieffer Tara Lynn, Directeur du Développement de Produits. Director active across 1 company, notably Enanta Pharmaceuticals INC. In total, 15 filings have been recorded. Breakdown: 0 buy · 4 sells. Total volume traded: €145k. History available since 19 November 2021. The latest transaction was disclosed on 12 February 2026 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
15 条申报中的 15 条
Kieffer Tara Lynn is Directeur du Développement de Produits. She has 15 filings in total, all within the recent sample covered from 2021-11-23 to 2026-02-13, with 0 in purchases and 145416 in sales. The company mentioned is Enanta Pharmaceuticals INC, where the listed role is Chief Product Strategy Officer, and the most common transaction nature is Attribution.